Toxic epidermal necrolysis after immune checkpoint inhibition, case report, and review of the literature

References

• Conroy M, Naidoo J. Immune-related adverse events and the balancing act of immunotherapy. Nat Commun. 2022;13(1):392.
   PubMed Web of Science ®Google Scholar
• Wang DY, Salem JE, Cohen JV, et al. Fatal toxic effects associated with immune checkpoint inhibitors: a systematic review and meta-analysis. JAMA Oncol. 2018;4(12):1721–1728.
   PubMed Web of Science ®Google Scholar
• Long GV, Atkinson V, Cebon JS, et al. Standard-dose pembrolizumab in combination with reduced-dose ipilimumab for patients with advanced melanoma (KEYNOTE-029): an open-label, phase 1b trial. Lancet Oncol. 2017;18(9):1202–1210.
   PubMed Web of Science ®Google Scholar
• Nadelmann ER, Yeh JE, Chen ST. Management of cutaneous immune-related adverse events in patients with cancer treated with immune checkpoint inhibitors: a systematic review. JAMA Oncol. 2022;8(1):130.
   PubMed Web of Science ®Google Scholar
• Zhu J, Chen G, He Z, et al. Stevens-Johnson syndrome/toxic epidermal necrolysis in patients treated with immune checkpoint inhibitors: a safety analysis of clinical trials and FDA pharmacovigilance database. EClinicalMedicine. 2021;37:100951.
   PubMedGoogle Scholar
• Lerch M, Mainetti C, Terziroli Beretta-Piccoli B, et al. Current perspectives on Stevens-Johnson syndrome and toxic epidermal necrolysis. Clinic Rev Allerg Immunol. 2018;54(1):147–176.
   PubMed Web of Science ®Google Scholar
• Palmieri TL, Greenhalgh DG, Saffle JR, et al. A multicenter review of toxic epidermal necrolysis treated in U.S. burn centers at the end of the twentieth century. J Burn Care Rehabil. 2002;23(2):87–96.
   PubMedGoogle Scholar
• Downey A, Jackson C, Harun N, et al. Toxic epidermal necrolysis: review of pathogenesis and management. J Am Acad Dermatol. 2012;66(6):995–1003.
   PubMed Web of Science ®Google Scholar
• Castillo B, Vera N, Ortega-Loayza AG, et al. Wound care for Stevens-Johnson syndrome and toxic epidermal necrolysis. J Am Acad Dermatol. 2018;79(4):764–767.
   PubMed Web of Science ®Google Scholar
• Lindford AJ, Kaartinen IS, Virolainen S, et al. Comparison of suprathel(R) and allograft skin in the treatment of a severe case of toxic epidermal necrolysis. Burns. 2011;37(7):e67–e72.
   PubMedGoogle Scholar
• Noe MH, Micheletti RG. Diagnosis and management of Stevens-Johnson syndrome/toxic epidermal necrolysis. Clin Dermatol. 2020;38(6):607–612.
   PubMed Web of Science ®Google Scholar
• Bai R, Chen N, Chen X, et al. Analysis of characteristics and predictive factors of immune checkpoint inhibitor-related adverse events. Cancer Biol Med. 2021;18(4):1118–1133.
   Web of Science ®Google Scholar
• Brahmer JR, Lacchetti C, Schneider BJ, in oration with the National Comprehensive Cancer Network, et al. Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American society of clinical oncology clinical practice guideline. J Clin Oncol. 2018;36(17):1714–1768.
   PubMed Web of Science ®Google Scholar
• Zimmermann S, Sekula P, Venhoff M, et al. Systemic immunomodulating therapies for Stevens-Johnson syndrome and toxic epidermal necrolysis: a systematic review and Meta-analysis. JAMA Dermatol. 2017;153(6):514–522.
   PubMed Web of Science ®Google Scholar
• Tsai TY, Huang IH, Chao YC, et al. Treating toxic epidermal necrolysis with systemic immunomodulating therapies: a systematic review and network Meta-analysis. J Am Acad Dermatol. 2021;84(2):390–397.
   PubMed Web of Science ®Google Scholar
• Zhang S, Tang S, Li S, et al. Biologic TNF-alpha inhibitors in the treatment of Stevens-Johnson syndrome and toxic epidermal necrolysis: a systemic review. J Dermatolog Treat. 2020;31(1):66–73.
   PubMed Web of Science ®Google Scholar
• Bai X, Hu J, Betof Warner A, et al. Early use of high-dose glucocorticoid for the management of irAE is associated with poorer survival in patients with advanced melanoma treated with anti-PD-1 monotherapy. Clin Cancer Res. 2021;27(21):5993–6000.
   PubMed Web of Science ®Google Scholar
• Elkrief A, Derosa L, Kroemer G, et al. The negative impact of antibiotics on outcomes in cancer patients treated with immunotherapy: a new independent prognostic factor? Ann Oncol. 2019;30(10):1572–1579.
   PubMed Web of Science ®Google Scholar
• Bessede A, Marabelle A, Guegan JP, et al. Impact of acetaminophen on the efficacy of immunotherapy in cancer patients. Ann Oncol. 2022. DOI:10.1016/j.annonc.2022.05.010
   Web of Science ®Google Scholar
• Choi EC, Heng YK, Lim YL. Immune checkpoint inhibitor-related Stevens-Johnson syndrome/toxic epidermal necrolysis-like reactions. J Am Acad Dermatol. 2021;85(2):e109.
   PubMed Web of Science ®Google Scholar
• Molina GE, Yu Z, Foreman RK, et al. Generalized bullous mucocutaneous eruption mimicking Stevens-Johnson syndrome in the setting of immune checkpoint inhibition: a multicenter case series. J Am Acad Dermatol. 2020;83(5):1475–1477.
   PubMed Web of Science ®Google Scholar
• Barvaliya M, Sanmukhani J, Patel T, et al. Drug-induced Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and SJS-TEN overlap: a multicentric retrospective study. J Postgrad Med. 2011;57(2):115–119.
   PubMed Web of Science ®Google Scholar